Ultragenyx stock plummets 25% after Phase 3 OI trial continues without early stop

Why did Ultragenyx Pharmaceutical’s stock drop more than 25% despite Phase 3 trial progress on UX143?

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) saw its stock plunge over 25% to $31.03 by midday on July 10, 2025, following a pivotal update on the Phase 3 Orbit study of UX143 (setrusumab) for osteogenesis imperfecta (OI). The American biotech company, in collaboration with Mereo BioPharma Group plc (NASDAQ: MREO), announced late on July 9 that the study would proceed to its final analysis without an early stop for efficacy. While the Data Monitoring Committee confirmed an acceptable safety profile and ongoing study integrity, investors appeared disappointed that interim data did not trigger an early halt, leading to sharp selloffs during morning trading.

Ultragenyx’s market capitalization dropped to approximately $2.93 billion in intraday trading, from a previous closing valuation of nearly $4 billion. The one-day decline, amounting to a $10.40 loss per share, positions July 10 as one of the steepest single-session drops in the biotech developer’s recent history.

What are the details of the UX143 Phase 3 Orbit and Cosmic studies for osteogenesis imperfecta treatment?

The pivotal Phase 3 Orbit study is evaluating UX143 (setrusumab), a sclerostin-inhibiting monoclonal antibody, in pediatric and young adult patients aged 5 to 25 with subtypes I, III, and IV of osteogenesis imperfecta. This global, randomized, placebo-controlled study enrolled 159 patients at 45 sites across 11 countries. Participants were randomized 2:1 to receive setrusumab or placebo, with the primary endpoint being the annualized clinical fracture rate. Following the primary analysis, all patients are expected to transition to an open-label extension receiving active treatment.

Simultaneously, the Phase 3 Cosmic study involves children aged 2 to under 7 years in a head-to-head comparison of setrusumab versus intravenous bisphosphonate therapy. Encompassing 69 patients across 21 sites in seven countries, this study is similarly targeting fracture rate reduction. Both studies require at least 18 months of therapy before the final analyses can be conducted. Statistical significance thresholds were pre-defined at p<0.04 for Orbit and p<0.05 for Cosmic.

Despite the market reaction, Ultragenyx reaffirmed that study conduct remains on track and that final data from both trials is expected around year-end. The decision not to stop early aligns with the original statistical plan and is not necessarily indicative of clinical failure.

Why are investors reacting negatively even though the clinical program remains on track?

Institutional sentiment appears to reflect high expectations that interim data would prompt an early efficacy halt, a possibility that could have significantly accelerated regulatory filings and commercial timelines. Analysts suggest that the absence of such a trigger, despite no safety concerns, implies that UX143 may not be demonstrating overwhelming early efficacy—at least not at the interim threshold required.

Ultragenyx’s CEO Emil D. Kakkis acknowledged that while an early stop was hoped for, the continued dosing and scheduled final analyses reinforce their confidence in the treatment’s effect on bone mass, fracture reduction, and functional outcomes. Nevertheless, biotech investors often price in binary outcomes at data readouts. Without a positive surprise, downside reactions are amplified, especially when paired with high expectations and elevated pre-announcement valuations.

The selloff may also reflect sector-wide caution toward late-stage rare disease programs following a recent spate of regulatory delays and commercial underperformance in similar indications. With no globally approved therapies for OI, UX143 represents a high-risk, high-reward pipeline asset that was being closely tracked by both long-only funds and speculative traders.

What makes UX143 a potentially transformative therapy in osteogenesis imperfecta?

Setrusumab (UX143) is a fully human monoclonal antibody that inhibits sclerostin—a protein that negatively regulates bone formation. By blocking sclerostin, the therapy aims to enhance bone mineral density and structural integrity in patients with OI, a group of genetic disorders characterized by brittle bones and high fracture risk.

Preclinical and early clinical evidence, including results from Mereo BioPharma’s Phase 2b ASTEROID study in adults, indicated clear dose-dependent improvements in bone mass and strength. Ultragenyx’s program, by expanding development to pediatric and adolescent populations, seeks to address a key unmet medical need and potentially deliver the first disease-modifying treatment for OI globally.

If successful in Phase 3, UX143 could unlock a significant market opportunity. Approximately 60,000 people are affected by OI in commercially accessible regions, and the treatment could qualify for accelerated pathways, having already received orphan drug, PRIME, and Breakthrough Therapy designations from U.S. and European regulators.

How does this impact Ultragenyx’s development timeline and investor expectations going forward?

Ultragenyx stated that both Orbit and Cosmic studies are proceeding toward their final data readouts, expected around the end of 2025. While that aligns with previous guidance, the lack of early efficacy signals resets expectations on a faster approval or launch path. This may also impact upcoming earnings sentiment, as UX143 is considered one of the most valuable assets in Ultragenyx’s rare disease pipeline.

The selloff sharply contrasts with the 12-month price target estimate of $89.84 per share, suggesting that either recovery is possible if final data is positive, or that analyst projections may be subject to downward revision. With current trading volume at over 8.5 million shares—roughly eight times the daily average—it is clear that sentiment is being recalibrated in real time.

Analysts caution that while the scientific rationale for setrusumab remains intact, final data will need to demonstrate statistically and clinically meaningful fracture reduction to justify market re-entry and long-term commercial value. Investor focus will now shift to the final analysis, extension period design, and regulatory clarity in early 2026.

What are the broader implications for Mereo BioPharma and the OI treatment market?

For Mereo BioPharma, the UX143 development represents both scientific and financial upside. The company retains EU and UK commercial rights and is eligible for up to $245 million in milestone payments and royalties on sales in Ultragenyx territories. However, its stock (NASDAQ: MREO) could also see short-term volatility based on Ultragenyx’s sentiment spillover.

The osteogenesis imperfecta treatment landscape remains wide open, with no approved therapies targeting the underlying collagen defects or bone metabolism imbalances. UX143’s success or failure could define the competitive landscape for years, potentially drawing new entrants or triggering consolidation interest depending on how final data evolves.